There are 449 resources available
1MO - A phase IIIb study of savolitinib in patients with locally advanced or metastatic NSCLC harboring MET exon 14 mutation
Presenter: yongchang zhang
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Session: Overcoming IO resistance
Resources:
Webcast
Exercise in lung cancer: Time to get moving
Presenter: Morten Quist
Session: Optimising treatment for special populations
Resources:
Slides
Webcast
137MO - Phase II study of becotarug (JMT101) combined with osimertinib in patients (pts) with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion (ex20ins) mutations (BECOME study)
Presenter: Zhang Li
Session: Mini Oral session 1
Resources:
Abstract
Q&A and discussion
Session: Optimising treatment for special populations
Resources:
Webcast
2MO - Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR exon 20 insertion-mutated advanced NSCLC: Analysis of post-progression endpoints from PAPILLON
Presenter: Enriqueta Felip
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 1MO, 137MO and 2MO
Presenter: Antonio Passaro
Session: Mini Oral session 1
Resources:
Slides
Webcast
Q&A
Session: Mini Oral session 1
Resources:
Webcast
Introduction and first vote
Presenter: Rolf Stahel
Session: The pros and cons of PROs
Resources:
Slides
Webcast
IO in early disease: Clinical decisions
Presenter: Kersti Oselin
Session: IO in early disease
Resources:
Slides
Webcast